Published 09/17/2024 5:00:10 a.m.

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Summary by Endpoints News

BARCELONA — A month after gutting its internal drug discovery group, 23andMe is trudging along with the experimental medicines it’s already brought into the clinic. 23andMe has struggled with its dual identity as a human genetics company and drug R&D outfit. It’s now getting into the GLP-1 arena, and its

0 Articles

All

Left

Center

Right

Endpoints News

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

09/17/2024 5:00:10 a.m.

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated09/17/2024 8:09:19 a.m.Bias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

0 Articles

0 Articles

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics